Regenxbio's rolling BLA submission completion of RGX-121 for the treatment of patients with MPS II expected in Q1 of 2025.

The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal ...

Mississauga, Ontario Tuesday, January 21, 2025, 14:00 Hrs [IST] ...

US-based biotechnology company Ocugen has dosed the first subject in a multicentre Phase I trial of OCU200 for diabetic ...

On completion of the scans and tests, he said: “You have early age-related macular degeneration.” When he saw my face fall, he added: “AMD – it’s very common.” My grandmother suffered.

Vabysmo Product Monograph, December 13, 2024. 2. Song P, et al. Global epidemiology of retinal vein occlusion: a systematic review and meta-analysis of prevalence, ...

Germany’s Formycon and its licensing partner Klinge Biopharma have announced that the European Commission (EC) has granted ...

Outlook (OTLK) stock fell 10% after the company said it had completed a study analysis for its drug ONS-5010 and entered into ...

Ocugen (OCGN) announced that the first patient has been dosed in the OCU200 Phase 1 clinical trial for diabetic macular edema, DME. “OCU200 has ...

Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and ...

Regulatory ApprovalFormycon receives EU approval for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand names AHZANTIVE® and Baiama® 20.01.2025 / 06:30 CET/CESTThe issuer is solely ...